Document is current
Any future updates will be listed below
-
Authors
Louca, Panayiotis
Štambuk, Tamara
Frkatović-Hodžić, Azra
Nogal, Ana
Mangino, Massimo
Berry, Sarah E.
Deriš, Helena
Hadjigeorgiou, George
Wolf, Jonathan
Vinicki, Martina
Franks, Paul W.
Valdes, Ana M.
Spector, Tim D.
Lauc, Gordan
Menni, Cristina https://orcid.org/0000-0001-9790-0571
-
Funding
Funding for this research was provided by:
Chronic Disease Research Foundation (CDRF–15/2018)
Wellcome Trust (212904/Z/18/Z)
European Structural and Investment Funds IRI "CardioMetabolic" grant (KK.01.2.1.02.0321)
- License Information
-
More Information
Article History
Received: 27 January 2023
Accepted: 13 June 2023
First Online: 3 July 2023
Declarations
:
: In accordance with the declaration of Helsinki, all participants provided informed written consent, and the study was approved by the Research Ethics Committee and Integrated Research Application System (IRAS 236407). The trial was registered on ClinicalTrials.gov (registration number: NCT03479866).
: Not applicable.
: GL is the founder and CEO of Genos Ltd, a private research organisation that specialises in high throughput glycomics analysis and has several patents in this field. TŠ, AF, HD, and MV are employees of Genos Ltd. TDS is co-founder and shareholder of ZOE Ltd. AMV and SEB receive options and are consultants for ZOE Ltd. JW is an employee of ZOE Ltd. All other authors have nothing to disclose.
